Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest Financial Results

FY 2022

Fiscal Year Ended Dec 31, 2022

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Stock Information

Company Overview

Vyant Bio, Inc. is a leader in drug discovery and preclinical oncology and immuno-oncology services enhancing the development of advanced therapies in precision medicine. Leveraging our expertise, we are looking beyond preclinical services to translational sciences and advanced drug discovery disease models as we position Vyant Bio for financial stability and future growth.

Vyant Bio is focused on extending its history of leading in the innovation of proprietary products and superior services through investments in unique technologies. To achieve this, we have developed a corporate culture that inspires innovation, respects knowledge and fosters leadership. We are actively pursuing strategic actions to further accelerate our growth in the field of drug discovery.

Investor Contact Information


Vyant Bio, Inc.
2370 State Route 70 West
Suite 310
Cherry Hill, NJ 08002
T: 201-479-1357

Investor Relations

Vyant Bio, Inc.
Andrew D. C. LaFrence
President, Chief Executive Officer and Chief Financial Officer
M: 612-802-9299

Transfer Agent

Continental Stock Transfer & Trust Company
Monty Harry, Senior Account Manager
17 Battery Place
8th Floor
New York, NY 10004
T: 212-845-3277
F: 212-616-7615